Optimising functional outcomes in schizophrenia
International expert, Professor Philip Gorwood, explores the role of long-acting injectables (LAIs) in preserving functioning in schizophrenia, including an analysis of the key findings from the QUALIFY study, a head-to-head study of Abilify Maintena® once-monthly and paliperidone palmitate once-monthly in adult patients (18–60 years).1* He also provides practical insights into aligning treatment choices with patient preference and when to consider introducing a LAI.
*QUALIFY: 28-week, randomised, non-inferiority, open-label, rater-blinded (with respect to Heinrichs–Carpenter Quality of Life Scale (QLS) and Investigator-Assessed Questionnaire [IAQ]), head-to-head study of aripiprazole 400 mg once-monthly and paliperidone palmitate once-monthly in adult patients (18–60 years). The primary endpoint assessed non-inferiority and superiority on QLS total score analysed using mixed model for repeated measurements. The dose of paliperidone palmitate once-monthly was 50–150 mg/month in Europe and Canada or 78–234 mg/month in the USA.1
